Erythropoietin in cardiac disease: Effective or harmful?

Vittoria Mastromarino, Maria B. Musumeci, Elena Conti, Giuliano Tocci, Massimo Volpe

Research output: Contribution to journalArticle

Abstract

Discovered as the primary regulator of erythropoiesis, erythropoietin (EPO) is involved in a broad variety of processes that play a major role in cardiovascular diseases. In particular, the antiapoptotic and pro-angiogenic properties of EPO have prompted a growing interest in the use of EPO for the treatment of myocardial infarction and heart failure. In a variety of myocardial ischemic injury animal models, EPO administration has been shown to acutely reduce infarct size, thereby preserving ventricular function. In addition, cardiac long-term effects of EPO, such as prevention of ventricular remodeling and heart failure, have been described. In recent years, several trials have tested the effects of recombinant human erythropoietin (rhEPO) administration in patients with myocardial infarction and chronic heart failure, in the attempt to translate the cardioprotection found in experimental models to human patients. In view of the generally controversial findings, in this updated review we provide an overview of the results of the most recent trials that investigated the role of erythropoiesis-stimulating agents (ESAs), including rhEPO and its analogue darbepoetin, in the treatment of acute myocardial infarction and heart failure. The problems related to safety and tolerability of ESA therapy are also discussed. Our analysis of the available literature demonstrates that the results of clinical studies in patients with cardiac disease are not uniform and the conclusions are contradictory. Further larger prospective studies are required to test clinical efficacy and safety of EPO.

Original languageEnglish
Pages (from-to)870-878
Number of pages9
JournalJournal of Cardiovascular Medicine
Volume14
Issue number12
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Erythropoietin
Heart Diseases
Heart Failure
Hematinics
Myocardial Infarction
Safety
Ventricular Remodeling
Ventricular Function
Erythropoiesis
Theoretical Models
Cardiovascular Diseases
Therapeutics
Animal Models
Prospective Studies
Wounds and Injuries

Keywords

  • Anemia
  • Cerebrovascular thromboembolism
  • Congestive heart failure
  • Erythropoietin
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Erythropoietin in cardiac disease : Effective or harmful? / Mastromarino, Vittoria; Musumeci, Maria B.; Conti, Elena; Tocci, Giuliano; Volpe, Massimo.

In: Journal of Cardiovascular Medicine, Vol. 14, No. 12, 12.2013, p. 870-878.

Research output: Contribution to journalArticle

Mastromarino, Vittoria ; Musumeci, Maria B. ; Conti, Elena ; Tocci, Giuliano ; Volpe, Massimo. / Erythropoietin in cardiac disease : Effective or harmful?. In: Journal of Cardiovascular Medicine. 2013 ; Vol. 14, No. 12. pp. 870-878.
@article{4c1b8ef291c74b44b377371eebc6fe2a,
title = "Erythropoietin in cardiac disease: Effective or harmful?",
abstract = "Discovered as the primary regulator of erythropoiesis, erythropoietin (EPO) is involved in a broad variety of processes that play a major role in cardiovascular diseases. In particular, the antiapoptotic and pro-angiogenic properties of EPO have prompted a growing interest in the use of EPO for the treatment of myocardial infarction and heart failure. In a variety of myocardial ischemic injury animal models, EPO administration has been shown to acutely reduce infarct size, thereby preserving ventricular function. In addition, cardiac long-term effects of EPO, such as prevention of ventricular remodeling and heart failure, have been described. In recent years, several trials have tested the effects of recombinant human erythropoietin (rhEPO) administration in patients with myocardial infarction and chronic heart failure, in the attempt to translate the cardioprotection found in experimental models to human patients. In view of the generally controversial findings, in this updated review we provide an overview of the results of the most recent trials that investigated the role of erythropoiesis-stimulating agents (ESAs), including rhEPO and its analogue darbepoetin, in the treatment of acute myocardial infarction and heart failure. The problems related to safety and tolerability of ESA therapy are also discussed. Our analysis of the available literature demonstrates that the results of clinical studies in patients with cardiac disease are not uniform and the conclusions are contradictory. Further larger prospective studies are required to test clinical efficacy and safety of EPO.",
keywords = "Anemia, Cerebrovascular thromboembolism, Congestive heart failure, Erythropoietin, Myocardial infarction",
author = "Vittoria Mastromarino and Musumeci, {Maria B.} and Elena Conti and Giuliano Tocci and Massimo Volpe",
year = "2013",
month = "12",
doi = "10.2459/JCM.0b013e328362c6ae",
language = "English",
volume = "14",
pages = "870--878",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Erythropoietin in cardiac disease

T2 - Effective or harmful?

AU - Mastromarino, Vittoria

AU - Musumeci, Maria B.

AU - Conti, Elena

AU - Tocci, Giuliano

AU - Volpe, Massimo

PY - 2013/12

Y1 - 2013/12

N2 - Discovered as the primary regulator of erythropoiesis, erythropoietin (EPO) is involved in a broad variety of processes that play a major role in cardiovascular diseases. In particular, the antiapoptotic and pro-angiogenic properties of EPO have prompted a growing interest in the use of EPO for the treatment of myocardial infarction and heart failure. In a variety of myocardial ischemic injury animal models, EPO administration has been shown to acutely reduce infarct size, thereby preserving ventricular function. In addition, cardiac long-term effects of EPO, such as prevention of ventricular remodeling and heart failure, have been described. In recent years, several trials have tested the effects of recombinant human erythropoietin (rhEPO) administration in patients with myocardial infarction and chronic heart failure, in the attempt to translate the cardioprotection found in experimental models to human patients. In view of the generally controversial findings, in this updated review we provide an overview of the results of the most recent trials that investigated the role of erythropoiesis-stimulating agents (ESAs), including rhEPO and its analogue darbepoetin, in the treatment of acute myocardial infarction and heart failure. The problems related to safety and tolerability of ESA therapy are also discussed. Our analysis of the available literature demonstrates that the results of clinical studies in patients with cardiac disease are not uniform and the conclusions are contradictory. Further larger prospective studies are required to test clinical efficacy and safety of EPO.

AB - Discovered as the primary regulator of erythropoiesis, erythropoietin (EPO) is involved in a broad variety of processes that play a major role in cardiovascular diseases. In particular, the antiapoptotic and pro-angiogenic properties of EPO have prompted a growing interest in the use of EPO for the treatment of myocardial infarction and heart failure. In a variety of myocardial ischemic injury animal models, EPO administration has been shown to acutely reduce infarct size, thereby preserving ventricular function. In addition, cardiac long-term effects of EPO, such as prevention of ventricular remodeling and heart failure, have been described. In recent years, several trials have tested the effects of recombinant human erythropoietin (rhEPO) administration in patients with myocardial infarction and chronic heart failure, in the attempt to translate the cardioprotection found in experimental models to human patients. In view of the generally controversial findings, in this updated review we provide an overview of the results of the most recent trials that investigated the role of erythropoiesis-stimulating agents (ESAs), including rhEPO and its analogue darbepoetin, in the treatment of acute myocardial infarction and heart failure. The problems related to safety and tolerability of ESA therapy are also discussed. Our analysis of the available literature demonstrates that the results of clinical studies in patients with cardiac disease are not uniform and the conclusions are contradictory. Further larger prospective studies are required to test clinical efficacy and safety of EPO.

KW - Anemia

KW - Cerebrovascular thromboembolism

KW - Congestive heart failure

KW - Erythropoietin

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84890127361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890127361&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e328362c6ae

DO - 10.2459/JCM.0b013e328362c6ae

M3 - Article

C2 - 23811836

AN - SCOPUS:84890127361

VL - 14

SP - 870

EP - 878

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 12

ER -